Quick Answer
AVENUE THERAPEUTICS, INC. reported Research And Development Expense of $1.04 million for the year ending 2025.
- AVENUE THERAPEUTICS, INC. showed a decrease of -84.4% in Research And Development Expense from 2024 to 2025.
- This data is from AVENUE THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2015 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2015 to 2025), AVENUE THERAPEUTICS, INC.'s Research And Development Expense has grown by 7.9%.
- Historical annual values: Fiscal year 2025: $1.04 million | Fiscal year 2024: $6.65 million | Fiscal year 2023: $6.13 million | Fiscal year 2022: $2.70 million | Fiscal year 2022: $300.0 thousand | Fiscal year 2021: $1.25 million | Fiscal year 2020: $2.87 million | Fiscal year 2019: $22.19 million | Fiscal year 2018: $17.70 million | Fiscal year 2017: $6.70 million | Fiscal year 2016: $1.33 million | Fiscal year 2015: $961.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: